Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells.
Sign Up to like & getrecommendations! Published in 2019 at "Vaccine"
DOI: 10.1016/j.vaccine.2019.09.044
Abstract: Ebola virus disease is an urgent international priority. Promising results for several vaccine candidates have been reported in non-human primate studies and clinical trials with the most promising being the rVSV-ZEBOV vaccine. In this study,… read more here.
Keywords: production; hek 293sf; rvsv zebov; 293sf cells ... See more keywords
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013–2016 West Africa Ebola outbreak in Guinea
Sign Up to like & getrecommendations! Published in 2020 at "Vaccine"
DOI: 10.1016/j.vaccine.2020.04.066
Abstract: Highlights • We found rVSVΔG-ZEBOV-GP to be immunogenic at 28- and 180-days post vaccination.• At 28 days post-vaccination, seroresponse rate was higher in the high-risk group.• There is a significant pairwise correlation at 28 days… read more here.
Keywords: response; rvsv zebov; days post; post vaccination ... See more keywords
PO 8559 ASSESSMENT OF THE EFFECT OF RVSV REPLICATION ON NON-EBOLA CIRCULATING ANTIBODIES IN RVSV-ZEBOV-GP-VACCINATED INDIVIDUALS IN LAMBARÉNÉ, GABON
Sign Up to like & getrecommendations! Published in 2019 at "BMJ Global Health"
DOI: 10.1136/bmjgh-2019-edc.138
Abstract: Background The West Africa Ebola virus disease (EVD) outbreak between 2015 and 2016 accelerated the need for safe and effective vaccines. Among candidate vaccines in clinical development, the recombinant Vesicular stomatitis virus (VSV) vectored with… read more here.
Keywords: circulating antibodies; replication non; virus; zebov ... See more keywords
Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
Sign Up to like & getrecommendations! Published in 2017 at "PLoS Medicine"
DOI: 10.1371/journal.pmed.1002402
Abstract: Background The rVSVΔG-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 × 107 plaque-forming units (PFU) in a trial in Guinea. This study provides further safety and immunogenicity data. Methods and findings A randomised,… read more here.
Keywords: trial; immunogenicity; safety; zebov ... See more keywords